Article thumbnail

Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle

By Andreas Rank, Oliver Weigert and Helmut Ostermann

Abstract

Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the peripheral circulation have been recognized as the primary pathopysiological mechanism in chronic immune thrombocytopenia (ITP). Recently, increasing evidence supports the co-existence of insufficient megakaryopoiesis. Inadequate low thrombopoietin (TPO) levels are associated with insufficient proliferation and differentiation of megakaryocytes, decreased proplatelet formation, and subsequent platelet release. Recently two novel activators of TPO receptors have been made available: romiplostim and eltrombopag. In several phase III studies, both agents demonstrated increase of platelet counts in about 80% of chronic ITP patients within 2 to 3 weeks. These agents substantially broaden the therapeutic options for patients with chronic ITP although long-term results are still pending. This review will provide an update on the current conception of underlying mechanisms in ITP and novel, pathophysiologically based treatment options

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2880346
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura.
  2. Circulating dendritic cells subsets and CD4+ Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.
  3. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura.
  4. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity.
  5. Different specificities of plateletassociated and plasma autoantibodies to platelet GPIIb-IIIa in patients with chronic immune thrombocytopenic purpura.
  6. (2005). Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol.
  7. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
  8. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
  9. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
  10. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.
  11. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults.
  12. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
  13. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation.
  14. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura.
  15. (2004). How can we provide the best care for our patients with immune thrombocytopenic pupura? Mayo Clin
  16. How I treat idiopathic thrombocytopenic purpura (ITP).
  17. Human platelets display highaffinity receptors for thrombopoietin.
  18. (2000). Idiopathic thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura.
  19. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
  20. (1997). Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation. Blood Coagul Fibrinolysis.
  21. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.
  22. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics.
  23. International consensus report on the investigation and management of primary immune thrombocytopenia.
  24. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.
  25. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
  26. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis.
  27. (1995). Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.
  28. (1993). Management of asplenic patients.
  29. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura.
  30. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.
  31. Monoclonal antibody – specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies.
  32. (2004). Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther.
  33. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
  34. Phase 1/2 study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: update including extended treatment [abstract].
  35. Platelet antibody testing in idiopathic thrombocytopenic purpura.
  36. (2008). Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura. Ann Hematol.
  37. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ.
  38. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP).
  39. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias.
  40. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP).
  41. (2004). Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.
  42. (1990). Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases.
  43. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
  44. (1996). Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost.
  45. (1996). Serum thrombopoietin level in various hematological diseases. Stem Cells.
  46. Specificity of autoantibodies in autoimmune thrombocytopenia.
  47. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura.
  48. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.
  49. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
  50. The ITP syndrome: pathogenic and clinical diversity.
  51. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.
  52. (1998). Thrombopoetin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission.
  53. (1995). Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res.
  54. Vincristine-loaded platelets for autoimmune thrombocytopenic purpura.